We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+20.56%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$4.36B
AUM Growth
+$814M
Cap. Flow
+$435M
Cap. Flow %
9.98%
Top 10 Hldgs %
53.12%
Holding
130
New
25
Increased
23
Reduced
18
Closed
26

Top Buys

Rank Stock Value
1
BBIO icon
BridgeBio Pharma
BBIO
+$183M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$135M
3
ATNX
Athenex, Inc. Common Stock
ATNX
+$65.5M
4
NVRO
NEVRO CORP.
NVRO
+$44.9M
5
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$37.8M

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$89.6M
2
ASND icon
Ascendis Pharma A/S
ASND
+$76.6M
3
NVTA
Invitae Corporation
NVTA
+$17.6M
4
IRTC icon
iRhythm Holdings
IRTC
+$15M
5
ZGNX
Zogenix, Inc.
ZGNX
+$14.6M

Sector Composition

Rank Sector Weight
1 Healthcare 93.53%
2 Financials 0.76%
3 Technology 0.14%
4 Consumer Discretionary 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MTEM
51
DELISTED
Molecular Templates, Inc.
MTEM
$16.5M 0.38%
131,609
– –
MRKR icon
52
Marker Therapeutics
MRKR
$18.5M
$15.8M 0.36%
200,000
– –
BHC icon
53
Bausch Health
BHC
$1.75B
$15.1M 0.35%
600,000
– –
UROV
54
DELISTED
Urovant Sciences Ltd.
UROV
$14.8M 0.34%
1,875,426
+1,010,067
+117% +$8.29M
ADPT icon
55
Adaptive Biotechnologies
ADPT
$3.61B
$13.8M 0.32%
+285,000
New +$12.6M
MORF
56
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$12.9M 0.3%
+650,000
New +$12.3M
MOTS
57
DELISTED
Motus GI Holdings, Inc. Common Stock
MOTS
$12.8M 0.29%
14,035
+3,333
+31% +$3.72M
AXNX
58
DELISTED
Axonics, Inc. Common Stock
AXNX
$11.7M 0.27%
285,502
-400,254
-58% -$11.3M
IDYA icon
59
IDEAYA Biosciences
IDYA
$3.43B
$11.4M 0.26%
+1,141,484
New +$12.4M
FOMX
60
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$11.1M 0.25%
4,661,824
– –
LITS
61
Lite Strategy Inc
LITS
$32.4M
$11M 0.25%
220,022
– –
AGRX
62
DELISTED
Agile Therapeutics
AGRX
$10.4M 0.24%
4,213
– –
ALEC icon
63
Alector
ALEC
$169M
$9.32M 0.21%
511,731
– –
DXCM icon
64
DexCom
DXCM
$29B
$8.99M 0.21%
+240,000
New +$7.54M
ARWR icon
65
Arrowhead Research
ARWR
$12.1B
$8.77M 0.2%
330,738
– –
ACOR
66
DELISTED
Acorda Therapeutics
ACOR
$8.65M 0.2%
+9,394
New +$11.5M
SWAV
67
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$8.56M 0.2%
150,000
– –
MCRB icon
68
Seres Therapeutics
MCRB
$45M
$8.05M 0.18%
+125,000
New +$11.9M
SYBX
69
DELISTED
Synlogic
SYBX
$7.9M 0.18%
57,857
– –
ICPT
70
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$7.77M 0.18%
+97,600
New +$8.74M
ORTX
71
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$7.3M 0.17%
52,180
– –
THC icon
72
Tenet Healthcare
THC
$22.2B
$6.21M 0.14%
+300,633
New +$6.93M
VCRA
73
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
$6.21M 0.14%
194,400
+144,400
+289% +$4.61M
RYTM icon
74
Rhythm Pharmaceuticals
RYTM
$7.31B
$5.79M 0.13%
262,970
-240,000
-48% -$6.06M
TBIO
75
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$5.49M 0.13%
435,000
– –
1 2
3
4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q2 2019 Portfolio in Review

As of Q2 2019, Perceptive Advisors held 130 positions worth $4.36B, up 23% from $3.54B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Perceptive Advisors deployed $435M of net new capital in Q2 2019, opening 25 new positions and adding to 23 existing holdings. Its largest new stake was BridgeBio Pharma: 6,706,268 shares worth $181M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 92% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Array Biopharma Inc, an estimated $89.6M trimmed.

  • Perceptive Advisors's largest Q2 2019 buy was BridgeBio Pharma: 6,706,268 shares worth $181M.
  • Perceptive Advisors added most to Mirati Therapeutics, Inc. Common Stock in Q2 2019, an estimated $135M increase.
  • Perceptive Advisors's biggest Q2 2019 reduction was Array Biopharma Inc, cutting an estimated $89.6M.
  • Perceptive Advisors fully exited iRhythm Holdings in Q2 2019, selling an estimated $15M.
  • Perceptive Advisors's ten largest holdings make up 53% of its $4.36B portfolio in Q2 2019.
  • Perceptive Advisors opened 25 new positions and closed 26 in Q2 2019.
  • Perceptive Advisors's portfolio value rose 23% quarter-over-quarter to $4.36B.

Based on Perceptive Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.